Efficacy and safety of biologics for the treatment of moderate-to-severe psoriasis in older adults: a single-centre Italian experience.

Background: Demographic changes lead to a number of issues regarding the biological treatment of older patients with moderate-to-severe psoriasis.

Objectives: To investigate the efficacy and safety of biologics in older adults, substratifying the population based on age, comorbidities and previous therapies over a longer timespan (> 60 weeks).

Methods: A retrospective, single-centre study was conducted with patients aged ≥ 65 years with moderate-to-severe psoriasis who had been undergoing treatment with biologic drugs for > 60 weeks.

Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy).

Background: IL-23 inhibitors are the latest class of biologic drugs approved for moderate-to-severe psoriasis.

Objectives: to investigate real-life safety and efficacy of tildrakizumab.

Methods: demographic data, medical history, psoriasis disease history, PASI, DLQI, BSA, NAPSI were recorded at weeks 0, 12, 24, 36.

Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.

Background: Real-world data for guselkumab, the first interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis, are scarce. This study represents the first 60-week, real-life, multicenter, retrospective experience to investigate the effectiveness, safety, tolerability, and drug retention of guselkumab in psoriatic patients.

Research Design And Methods: Clinical information was collected at baseline and at weeks 12, 24, 36, 48, and 60.

[Klebsiella pneumoniae resistente ai carbapenemici: prevalenza delle infezione ematiche prima e dopo la pandemia da SARS-CoV-2 in un ospedale di livello terziario del Nord-Est italiano.].

Riassunto. La pandemia da covid-19 ha comportato un incremento dell'uso degli antibiotici e dell'antibiotico-resistenza negli ospedali, sia negli Stati Uniti che in Europa, causando un aumento della morbilità e della mortalità nei pazienti ospedalizzati per la covid-19. Come in altri ospedali anche noi abbiamo documentato un incremento delle colonizzazioni e infezioni da germi multiresistenti.

Therapeutic approaches and targets for treatment of autoimmune bullous diseases.

Autoimmune bullous diseases are a heterogeneous group of diseases characterized by the development of cutaneous and mucosal vesicles, blisters, and finally erosions. The common pathogenetic mechanism is the presence of autoantibodies targeting structural proteins of the skin and mucous membranes (demosomes and hemidesmosomes): in the case of pemphigus, the antigens are intraepidermal, whereas in the case of pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa acquisita they are subepidermal. Mucosal involvement typically affects the oral and ocular mucosa, but in some cases, the upper airways or the upper digestive tract are affected.